The rise of Viagra and its impact on the pharmaceutical landscape presents a complicated question for shareholders. While the first sales data were astounding, the exclusivity has expired, leading to a deluge of copycat alternatives that are chipping away at profit. In addition, the sector is facing issues related to population trends and shifting